Literature DB >> 33403997

Long-COVID: An evolving problem with an extensive impact.

M Mendelson1, J Nel, L Blumberg, S A Madhi, M Dryden, W Stevens, F W D Venter.   

Abstract

Persistence of symptoms or development of new symptoms relating to SARS-CoV-2 infection late in the course of COVID-19 is an increasingly recognised problem facing the globally infected population and its health systems. 'Long-COVID' or 'COVID long-haulers' generally describes those persons with COVID-19 who experience symptoms for >28 days after diagnosis, whether laboratory confirmed or clinical. Symptoms are as markedly heterogeneous as seen in acute COVID-19 and may be constant, fluctuate, or appear and be replaced by symptoms relating to other systems with varying frequency. Such multisystem involvement requires a holistic approach to management of long-COVID, and descriptions of cohorts from low- and middle-income countries are eagerly awaited. Although many persons with long-COVID will be managed in primary care, others will require greater input from rehabilitation medicine experts. For both eventualities, planning is urgently required to ensure that the South African public health service is ready and able to respond.

Entities:  

Year:  2020        PMID: 33403997     DOI: 10.7196/SAMJ.2020.v111i11.15433

Source DB:  PubMed          Journal:  S Afr Med J


  41 in total

1.  Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation.

Authors:  Ryan D Castle; Michelle A Williams; William C Bushell; J Adam Rindfleisch; Christine Tara Peterson; James Marzolf; Kimberly Brouwer; Paul J Mills
Journal:  J Inflamm Res       Date:  2021-09-22

2.  Caregiving in a Pandemic: Health-Related Socioeconomic Vulnerabilities Among Women Caregivers Early in the COVID-19 Pandemic.

Authors:  Kelly Boyd; Victoria Winslow; Soo Borson; Stacy Tessler Lindau; Jennifer A Makelarski
Journal:  Ann Fam Med       Date:  2022-09-02       Impact factor: 5.707

Review 3.  Rehabilitation Strategies for Cognitive and Neuropsychiatric Manifestations of COVID-19.

Authors:  Summer Rolin; Ashley Chakales; Monica Verduzco-Gutierrez
Journal:  Curr Phys Med Rehabil Rep       Date:  2022-05-14

4.  Long-COVID Headache.

Authors:  Paolo Martelletti; E Bentivegna; V Spuntarelli; M Luciani
Journal:  SN Compr Clin Med       Date:  2021-05-20

5.  Recognizing the Clinical Sequelae of COVID-19 in Adults: COVID-19 Long-Haulers.

Authors:  Sherry Leviner
Journal:  J Nurse Pract       Date:  2021-05-07       Impact factor: 0.767

6.  Postdischarge outcomes of COVID-19 patients from South Asia: a prospective study.

Authors:  Visula Abeysuriya; Suranjith L Seneviratne; Arjuna P De Silva; Riaz Mowjood; Shazli Mowjood; Thushara de Silva; Primesh de Mel; Chandima de Mel; R S Wijesinha; Amitha Fernando; Sanjay de Mel; Lal Chandrasena
Journal:  Trans R Soc Trop Med Hyg       Date:  2022-04-28       Impact factor: 2.455

Review 7.  Neurological Sequelae in Patients with COVID-19: A Histopathological Perspective.

Authors:  Francesco Fisicaro; Mario Di Napoli; Aldo Liberto; Martina Fanella; Flavio Di Stasio; Manuela Pennisi; Rita Bella; Giuseppe Lanza; Gelsomina Mansueto
Journal:  Int J Environ Res Public Health       Date:  2021-02-03       Impact factor: 3.390

8.  Ross River Virus Immune Evasion Strategies and the Relevance to Post-viral Fatigue, and Myalgic Encephalomyelitis Onset.

Authors:  Brett A Lidbury
Journal:  Front Med (Lausanne)       Date:  2021-03-24

9.  Mild to Severe Neurological Manifestations of COVID-19: Cases Reports.

Authors:  Gabriele Melegari; Veronica Rivi; Gabriele Zelent; Vincenzo Nasillo; Elena De Santis; Alessandra Melegari; Claudia Bevilacqua; Michele Zoli; Stefano Meletti; Alberto Barbieri
Journal:  Int J Environ Res Public Health       Date:  2021-04-01       Impact factor: 3.390

Review 10.  The Symptoms and Clinical Manifestations Observed in COVID-19 Patients/Long COVID-19 Symptoms that Parallel Toxoplasma gondii Infections.

Authors:  Kevin Roe
Journal:  J Neuroimmune Pharmacol       Date:  2021-05-29       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.